Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data-Reference-Cited by-同舟云学术

Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data

Published:2022-08-19 Issue:5 Volume:45 Page:3067-3081
ISSN:1437-2320
Container-title:Neurosurgical Review
language:en
Short-container-title:Neurosurg Rev

Author:

Jensen Lasse Rehné^ORCID,Maier Andrea Daniela^ORCID,Lomstein Atle,Graillon Thomas^ORCID,Hrachova Maya,Bota Daniela^ORCID,Ruiz-Patiño Alejandro^ORCID,Arrieta Oscar^ORCID,Cardona Andrés Felipe^ORCID,Rudà Roberta^ORCID,Furtner Julia^ORCID,Roeckle Ulrich,Clement Paul,Preusser Matthias^ORCID,Scheie David^ORCID,Broholm Helle,Kristensen Bjarne Winther^ORCID,Skjøth-Rasmussen Jane^ORCID,Ziebell Morten^ORCID,Munch Tina Nørgaard^ORCID,Fugleholm Kåre^ORCID,Walter Martin A.^ORCID,Mathiesen Tiit^ORCID,Mirian Christian^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10143-022-01849-6.pdf

Reference64 articles.

1. Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. https://doi.org/10.1023/B:NEON.0000013498.19981.55

2. Behling F, Fodi C, Skardelly M et al (2022) Differences in the expression of SSTR1–5 in meningiomas and its therapeutic potential. Neurosurg Rev 45:467–478. https://doi.org/10.1007/s10143-021-01552-y

3. Behling F, Fodi C, Skardelly M, Renovanz M, Castaneda S, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J (2021) Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential. Neurosurg Rev. https://doi.org/10.1007/s10143-021-01552-y

4. Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, A Ducar M, Thorner AR, van Hummelen P, O Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R (2017) Erratum: genomic landscape of high-grade meningiomas. NPJ Genom Med 2:26. https://doi.org/10.1038/s41525-017-0014-7

5. Cardona AF, Ruiz-Patiño A, Zatarain-Barrón ZL, Hakim F, Jiménez E, Mejía JA, Ramón JF, Useche N, Bermúdez S, Pineda D, Cifuentes H, Rojas L, Ricaurte L, Pino LE, Balaña C, Arrieta O (2019) Systemic management of malignant meningiomas: a comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS One 14:1–13. https://doi.org/10.1371/journal.pone.0217340

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytotoxicity on low-grade canine meningioma with the use of somatostatin analog (octreotide): An in vitro study;Neuro-Oncology Advances;2024-01-01

2. Meningioma animal models: a systematic review and meta-analysis;Journal of Translational Medicine;2023-10-28

3. Innovative treatments for meningiomas;Revue Neurologique;2023-06

4. Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives;International Journal of Molecular Sciences;2023-03-01

5. Hormone therapies in meningioma-where are we?;Journal of Neuro-Oncology;2022-11-23